GlassScriptPhysician profile
Raymon K Nelson
NPI 1346236452
$5,034.02
in general payments reported to CMS, 2019-2025
37 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2021: $708 · 2022: $894 · 2023: $1,224 · 2024: $934 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.18 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,019.32 | 2021-2025 | |
| Pfizer INC. | $680.61 | 2019-2025 | |
| Abbott Laboratories | $541.75 | 2023-2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $328.12 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $327.33 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $271.21 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $238.49 | 2021-2025 | Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $192.53 | 2021-2022 | |
| Medtronic, INC. | $171.22 | 2023 | Harmony |
| Actelion Pharmaceuticals US, INC. | $136.86 | 2023 | Opsumit, Uptravi |
| Boston Scientific Corporation | $108.98 | 2022-2025 | Watchman Flx |
| Gilead Sciences, INC. | $108.18 | 2019 | |
| Novo Nordisk INC | $105.65 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.60 | 2021-2024 | Jardiance |
| Amgen INC. | $92.83 | 2019-2023 | Repatha |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymon Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.